Cutia Therapeutics
HKEX:2487
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cutia Therapeutics
HKEX:2487
|
CN |
|
I
|
iLearningEngines Inc
OTC:AILEQ
|
US |
|
Orix JREIT Inc
TSE:8954
|
JP |
|
G
|
Gigastorage Corp
TWSE:2406
|
TW |
|
M
|
Mediatechnics Corp
OTC:MEDT
|
US |
|
H
|
Hitachi Zosen Corp
TSE:7004
|
JP |
Cutia Therapeutics
Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.
Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.
